Tissue Plasminogen Activator Concept

subject area of

• A High Affinity Interaction of Plasminogen with Fibrin Is Not Essential for Efficient Activation by Tissue-type Plasminogen Activator  Academic Article
• A New Short Infusion Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Venous Thromboembolic Disease  Academic Article
• A Pooled Analysis of Diffusion-Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage  Academic Article
• A Randomized Trial of a Single Bolus Dosage Regimen of Recombinant Tissue Plasminogen Activator in Patients with Acute Pulmonary Embolism  Academic Article
• ASPIRIN AND FIBRINOLYSIS  Academic Article
• Activated Partial Thromboplastin Time and Outcome After Thrombolytic Therapy for Acute Myocardial Infarction  Academic Article
• Activated thrombin‐activatable fibrinolysis inhibitor (TAFIa) attenuates fibrin‐dependent plasmin generation on thrombin‐activated platelets  Academic Article
• Acute Ischemic Stroke Therapy Overview  Academic Article
• Acute stroke management.  Academic Article
• Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.  Academic Article
• An Economic Evaluation of rt-PA Locking Solution in Dialysis Catheters  Academic Article
• An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction  Academic Article
• Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines  Academic Article
• Aspirin and fibrinolysis in acute myocardial infarction: Meta-analytic evidence for synergy  Academic Article
• Aspirin improves the outcome of intra-arterial thrombolysis with tissue plasminogen activator  Academic Article
• Benefit-risk ratios in the assessment of the clinical evidence of a new therapy  Academic Article
• Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID‐19: A single‐center prospective longitudinal study  Academic Article
• Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis  Academic Article
• Characterization of the Interactions of Plasminogen and Tissue and Vampire Bat Plasminogen Activators with Fibrinogen, Fibrin, and the Complex of d-Dimer Noncovalently Linked to Fragment E  Academic Article
• Comparison of the Efficacy of Pharmacoinvasive Management for ST-Segment Elevation Myocardial Infarction in Smokers Versus Non-Smokers (from the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction)  Academic Article
• Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial  Academic Article
• Coronary thrombolysis--clinical guidelines and public policy: results of an Ontario practitioner survey.  Academic Article
• Dabigatran-related coagulopathy: when can we assume the effect has “worn off”?  Academic Article
• Dialysis Catheters and Recombinant Tissue Plasminogen Activator  Academic Article
• Do plasma biomarkers of coagulation and fibrinolysis differ between patients who have experienced an acute myocardial infarction versus stable exertional angina?  Academic Article
• Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)?  Academic Article
• Effect of ascorbate on fibrinolytic factors in septic mouse skeletal muscle  Academic Article
• Effectiveness and safety of abciximab after failed thrombolytic therapy  Academic Article
• Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema  Academic Article
• Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction.  Academic Article
• Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD  Academic Article
• Embolization of the deep cervical collaterals—a unique endovascular approach to prevent repeated posterior fossa strokes refractory to medical therapy  Academic Article
• Emergence of the Primary Pediatric Stroke Center  Academic Article
• Endovascular Thrombectomy for Acute Ischemic Stroke  Academic Article
• Endovascular thrombectomy and intravenous alteplase in patients with acute ischemic stroke due to large vessel occlusion: A clinical practice guideline  Academic Article
• Endovascular thrombectomy with or without intravenous alteplase for acute ischemic stroke due to large vessel occlusion: a systematic review and meta-analysis of randomized trials  Academic Article
• Evaluation of low PAI‐1 activity as a risk factor for hemorrhagic diathesis  Academic Article
• FIBRIN CLOT LYSIS BY TISSUE PLASMINOGEN ACTIVATOR (tPA) IS IMPAIRED IN PLASMA FROM PEDIATRIC PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION  Academic Article
• Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists  Academic Article
• Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.  Academic Article
• Fibrinolytic System in Adolescents: Response to Venous Occlusion Stress Tests  Academic Article
• Fibrinolytic Variables in Patients with Recurrent Venous Thrombosis: a Prospective Cohort Study  Academic Article
• Fibrinolytic properties of lysine-derivatized polyethylene in contact with flowing whole blood (Chandler loop model)  Academic Article
• Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease  Academic Article
• Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activ  Academic Article
• Good is not Good Enough: The Benchmark Stroke Door-to-Needle Time Should be 30 Minutes  Academic Article
• Graded exercise testing following thrombolytic therapy for acute myocardial infarction: the importance of timing and infarct location. TPAT Study Group.  Academic Article
• Growth factors, tissue and urokinase-type plasminogen activators in venous ulcers.  Academic Article
• Heparin enhances active site-dependent binding of tissue-type plasminogen activator to endothelial cells  Academic Article
• Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.  Academic Article
• ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction  Academic Article
• Identification of the Mechanism Responsible for the Increased Fibrin Specificity of TNK-Tissue Plasminogen Activator Relative to Tissue Plasminogen Activator  Academic Article
• Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus  Academic Article
• Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type1 diabetic patients  Academic Article
• In acute ischemic stroke, early intraarterial treatment plus usual care improved functional independence  Academic Article
• In intermediate-risk acute PE, tenecteplase plus heparin reduced hemodynamic decompensation but increased stroke.  Academic Article
• In ischemic stroke, early intraarterial treatment plus alteplase improved reperfusion and functional outcome  Academic Article
• In-Hospital Delays for Acute Stroke Treatment Delivery During the COVID-19 Pandemic  Academic Article
• Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients  Academic Article
• Influence of Fibrinolytic Factors on Scar Formation After Lumbar Discectomy  Academic Article
• Influence of changes in lifestyle on fibrinolytic parameters and recurrence rate in patients with venous thromboembolism  Academic Article
• Interactions of fibrinolytic system proteins with lysine-containing surfaces  Academic Article
• Interactions of plasminogen and fibrinogen with model silica glass surfaces: Adsorption from plasma and enzymatic activity studies  Academic Article
• International differences in in-hospital revascularization and outcomes following acute myocardial infarction A multilevel analysis of patients in ASSENT-2  Academic Article
• Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial  Academic Article
• Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial  Academic Article
• Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity  Academic Article
• Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator.  Academic Article
• Limited Fibrin Specificity of Tissue-type Plasminogen Activator and Its Potential Link to Bleeding  Academic Article
• Lower levels of PAI-2 may contribute to impaired healing in venous ulcers - a preliminary study.  Academic Article
• Lysis of surface-localized fibrin clots by adsorbed plasminogen in the presence of tissue plasminogen activator  Academic Article
• Management of a Patient with Catheter-Related Bloodstream Infection  Academic Article
• Mechanism of Action of Plasminogen Activators  Academic Article
• Now You See It, Now You Don’t?  Academic Article
• Overutilization and underutilization of thrombolysis in routine clinical practice∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  Academic Article
• Patterns of Stroke Transfers and Identification of Predictors for Thrombectomy  Academic Article
• Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis  Academic Article
• Plasma Urokinase Antigen and Plasminogen Activator Inhibitor-1 Antigen Levels Predict Angiographic Coronary Restenosis  Academic Article
• Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor.  Academic Article
• Practical Model-Based Dose Finding in Early-Phase Clinical Trials  Academic Article
• Pre Admission Antithrombotics are Associated with Improved Outcomes following Ischaemic Stroke: A Cohort from the Registry of the Canadian Stroke Network  Academic Article
• Predicting tissue plasminogen activator use and success in in-center hemodialysis patients  Academic Article
• Prevention of Dialysis Catheter Malfunction with Recombinant Tissue Plasminogen Activator  Academic Article
• Prevention of catheter lumen occlusion with rT-PA versus heparin (Pre-CLOT): study protocol of a randomized trial [ISRCTN35253449]  Academic Article
• Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators.  Academic Article
• Reduced Dose Bolus Alteplase vs Conventional Alteplase Infusion for Pulmonary Embolism Thrombolysis  Academic Article
• Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial  Academic Article
• Reducing Door-to-Needle Time for Tissue Plasminogen Activator Administration in a Community Hospital: An Operations Study  Academic Article
• Regulation of plasminogen activator inhibitor-1 secretion by urokinase and tissue plasminogen activator in rat epithelioid-type smooth muscle cells  Academic Article
• Response to “Effect of Tissue Plasminogen Activator Dose and Interval on Stroke Severity”  Academic Article
• Results of a Prospective Randomized Trial Evaluating Surgery Versus Thrombolysis for Ischemia of the Lower Extremity The STILE Trial  Academic Article
• Seizures during stroke thrombolysis heralding dramatic neurologic recovery  Academic Article
• Selection and in vitro and in vivo characterization of a Kunitz protease inhibitor domain of protease nexin 2 variant that inhibits factor XIa without inhibiting plasmin  Academic Article
• Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.  Academic Article
• Stability and sterility of recombinant tissue plasminogen activator at −30°C  Academic Article
• Standard and Low Molecular Weight Heparin Have no Effect on Tissue Plasminogen Activator Induced Plasma Clot Lysis or Fibrinogenolysis  Academic Article
• Successful Use of Thrombolysis in an Extremely Low Birth Weight, Premature Infant With Aortic Thrombosis  Academic Article
• Successful delayed thrombolysis with tissue plasminogen activator for recurrent arterial thrombosis secondary to protein S deficiency  Academic Article
• Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure  Academic Article
• Surgical management of submacular hemorrhage: experience at an academic Canadian centre  Academic Article
• The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model  Academic Article
• The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial Infarction  Academic Article
• The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial  Academic Article
• The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial  Academic Article
• The relative kinetics of clotting and lysis provide a biochemical rationale for the correlation between elevated fibrinogen and cardiovascular disease  Academic Article
• The role of platelets and platelet inhibition in acute myocardial infarction  Academic Article
• The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabrits  Academic Article
• The use of alteplase to restore patency of central venous lines in pediatric patients: A cohort study  Academic Article
• Thrombin Binds to Soluble Fibrin Degradation Products Where it Is Protected From Inhibition by Heparin-Antithrombin but Susceptible to Inactivation by Antithrombin-Independent Inhibitors  Academic Article
• Thrombin-activable Fibrinolysis Inhibitor Attenuates (DD)E-mediated Stimulation of Plasminogen Activation by Reducing the Affinity of (DD)E for Tissue Plasminogen Activator  Academic Article
• Thrombolysis Despite Recent Stroke  Academic Article
• Thrombolysis by chemically modified coagulation factor Xa  Academic Article
• Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review.  Academic Article
• Thrombolysis in Acute Childhood Stroke: Design and Challenges of the Thrombolysis in Pediatric Stroke Clinical Trial  Academic Article
• Thrombolysis in Pediatric Stroke Study  Academic Article
• Thrombolysis with alteplase 3–4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances  Academic Article
• Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated?  Academic Article
• Thrombolytic therapy for the treatment of acute pulmonary embolism.  Academic Article
• Tissue Plasminogen Activator  Academic Article
• Tissue Plasminogen Activator Overdose in Acute Ischemic Stroke Patients Linked to Poorer Functional Outcomes  Academic Article
• Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers  Academic Article
• Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial.  Academic Article
• Tissue plasminogen activator-containing polyurethane surfaces for fibrinolytic activity  Academic Article
• Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction  Academic Article
• Treatment of acute ischemic stroke: from fibrinolysis to neurointervention  Academic Article
• Type 1 Plasminogen Activator Inhibitor Binds to Fibrin via Vitronectin  Academic Article
• Use of alteplase in childhood arterial ischaemic stroke: a multicentre, observational, cohort study  Academic Article
• Use of thrombolytic agents to treat neonatal thrombosis in clinical practice  Academic Article
• Utility of Intravenous Alteplase Prior to Endovascular Stroke Treatment  Academic Article
• Zinc delays clot lysis by attenuating plasminogen activation and plasmin-mediated fibrin degradation  Academic Article
• [Canadian Consensus Conference on Coronary Thrombolysis--current aspects].  Academic Article